Which formulation is preferred, metoprolol tartrate (immediate‑release) or metoprolol succinate (extended‑release)?

Metoprolol Succinate (Extended-Release) is Preferred Over Metoprolol Tartrate (Immediate-Release)

For heart failure with reduced ejection fraction (HFrEF), metoprolol succinate (extended-release) is the formulation proven to reduce mortality and should be used, not metoprolol tartrate. For other cardiovascular indications including acute STEMI, atrial fibrillation rate control, and hypertension, either formulation is acceptable, though metoprolol succinate offers the advantage of once-daily dosing with more stable drug levels.

Heart Failure: Metoprolol Succinate Only

In patients with HFrEF, only sustained-release metoprolol succinate has been proven to reduce mortality in large randomized trials. 1 The 2022 ACC/AHA/HFSA Heart Failure Guidelines specifically recommend "use of 1 of the 3 beta blockers proven to reduce mortality (e.g., bisoprolol, carvedilol, sustained-release metoprolol succinate)" as a Class I recommendation. 1

Critical Evidence Distinction

• Metoprolol succinate (target dose 200 mg once daily) demonstrated a 34% reduction in all-cause mortality in the MERIT-HF trial, along with a 41% reduction in sudden death and 19% reduction in the combined endpoint of mortality plus hospitalization. 2, 3

• Metoprolol tartrate (immediate-release) was directly compared to carvedilol in the COMET trial and showed inferior mortality reduction compared to carvedilol. 1 The ACC/AHA guidelines explicitly state: "Although both the dose and the formulation of metoprolol (metoprolol tartrate) used in the above-referenced trial are commonly prescribed by physicians for the treatment of HF, they were neither the dose nor the formulation used in the controlled trial that showed that sustained-release metoprolol (metoprolol succinate) reduces the risk of death." 1

This is not a class effect—the specific formulation matters for survival benefit in heart failure. 1

Acute STEMI: Either Formulation Acceptable

For ST-elevation myocardial infarction, the 2013 ACC/AHA STEMI guidelines recommend initiating oral beta blockers within the first 24 hours but do not mandate a specific formulation. 1 The guideline dosing table states: "Metoprolol tartrate 25 to 50 mg every 6 to 12 h orally, then transition over next 2 to 3 d to twice-daily dosing of metoprolol tartrate or to daily metoprolol succinate; titrate to daily dose of 200 mg as tolerated." 1

• Metoprolol tartrate can be initiated acutely with the advantage of IV formulation availability (5 mg every 5 minutes up to 3 doses) for immediate rate/blood pressure control. 1
• Transition to metoprolol succinate is reasonable for long-term management given once-daily convenience and more stable pharmacokinetics. 1

Atrial Fibrillation Rate Control: Either Formulation Acceptable

The 2014 AHA/ACC/HRS Atrial Fibrillation Guidelines list both formulations for rate control without preference. 1

• Metoprolol tartrate: 25–100 mg twice daily (oral maintenance) or 2.5–5.0 mg IV bolus over 2 minutes up to 3 doses (acute setting). 1
• Metoprolol succinate (XL): 50–400 mg once daily. 1

The choice depends on clinical context—IV metoprolol tartrate is preferred for acute rate control, while metoprolol succinate offers once-daily dosing for chronic management. 1

Hypertension: Metoprolol Succinate Preferred for Convenience

The 2017 ACC/AHA Hypertension Guidelines list both formulations but note that beta blockers are not first-line agents unless the patient has ischemic heart disease or heart failure. 1

• Metoprolol tartrate: 100–200 mg in 2 divided doses. 1
• Metoprolol succinate: 50–200 mg once daily. 1

Metoprolol succinate provides more consistent 24-hour blood pressure control with less fluctuation in plasma concentrations, making it preferable for adherence and sustained efficacy. 4, 5 Studies demonstrate that metoprolol succinate maintains relatively constant beta-blockade throughout the dosing interval, whereas immediate-release metoprolol produces larger peak effects but diminished trough effects at 24 hours. 6, 5

Pharmacokinetic Advantages of Metoprolol Succinate

Metoprolol succinate uses controlled-release technology that provides zero-order drug release over 24 hours, resulting in:

• Lower peak plasma concentrations (reducing peak-related adverse effects like excessive bradycardia or bronchospasm). 6, 5
• Higher trough concentrations at 24 hours (maintaining therapeutic effect throughout the dosing interval). 6, 5
• More consistent beta-blockade with less fluctuation (14-27% reduction in exercise heart rate maintained throughout 24 hours at doses of 50-400 mg). 6
• Better utilization of plasma concentrations for pharmacodynamic effect compared to immediate-release formulations. 5

In contrast, immediate-release metoprolol tartrate requires 2-4 times daily dosing to match the sustained beta-blockade achieved with once-daily metoprolol succinate. 6

Common Pitfalls to Avoid

• Do not use metoprolol tartrate for heart failure expecting the same mortality benefit as metoprolol succinate—the evidence does not support this substitution. 1
• Do not assume beta-blocker class effect in HFrEF—only bisoprolol, carvedilol, and metoprolol succinate have proven mortality reduction. 1
• Avoid abrupt cessation of either formulation, particularly in patients with ischemic heart disease. 1
• Monitor for beta-2 blockade effects (bronchospasm) at higher plasma concentrations (>300 nmol/L), though metoprolol succinate's lower peak levels reduce this risk compared to immediate-release formulations. 6